Loading…
Loading…
NIVF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NIVF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NIVF and 80,000+ other tickers.
See exactly how NIVF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NIVF and 80,000+ other tickers.
Operating out of its headquarters in Bangkok, Thailand, NewGenIvf Group Limited specializes in delivering assisted reproductive services. The firm is committed to fulfilling the desire for family through a variety of fertility treatments. Its extensive service portfolio includes conventional in-vitro fertilization (IVF), egg donation, and surrogacy, all complemented by comprehensive ancillary care.
BANGKOK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today announced that it has completed an exchange agreement with a certain institutional investor (“Investor”) pursuant to which existing convertible notes held by the Investor were exchanged for a new senior convertible note on amended terms. The exchange closed on August 14, 2026.
NewGen's total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen's agreed 13% stake in K25.ai is now valued at approximately US$26 million, based on K25.ai's recently closed Series A investment round, representing an unrealized gain of about US$8.5 million BANGKOK, July 30, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today provided an update on its strategic investment in K25.ai and the related impact on the Company's capitalization and financial position. NewGen reported net profit attributable to shareholders of US$9.9 million for the fiscal year ended December 31, 2025, with net assets of approximately US$25.98 million as of that date.
Follow-on investment would increase NewGen's aggregate ownership to 13% Follow-on investment would increase NewGen's aggregate ownership to 13%
K25.ai closes Series A investment round, reaching a post-money valuation of US$200 million NewGen's 10% ownership stake in K25.ai has reached US$20 million in value and generated a ~US$10 million unrealized gain, expected to be booked in 2026 BANGKOK, July 23, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today highlighted that K25.ai has closed its Series A investment round with strategic support from the Singapore-based digital assets firm Amber Group. The latest round values K25.ai at a post-money valuation of US$200 million, doubling its US$100 million Pre-A valuation in under 60 days.
/PRNewswire/ -- K25.ai, the AI-native prediction market transforming livestreams into real-time interactive markets, today announced the closing of its Series